$80,000 of ABBVIE INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues."
You can find more data on corporate lobbying on Quiver Quantitative.
ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABBV Insider Trading Activity
ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
- DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABBV Hedge Fund Activity
We have seen 1,719 institutional investors add shares of ABBV stock to their portfolio, and 1,737 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 37,400,173 shares (-74.3%) from their portfolio in Q4 2025, for an estimated $8,545,565,528
- CAPITAL WORLD INVESTORS added 6,736,161 shares (+106.3%) to their portfolio in Q4 2025, for an estimated $1,539,145,426
- BLACKROCK, INC. added 5,197,454 shares (+3.6%) to their portfolio in Q4 2025, for an estimated $1,187,566,264
- CARDANO RISK MANAGEMENT B.V. added 4,908,260 shares (+914.6%) to their portfolio in Q4 2025, for an estimated $1,121,488,327
- WELLINGTON MANAGEMENT GROUP LLP added 4,389,782 shares (+41.7%) to their portfolio in Q4 2025, for an estimated $1,003,021,289
- GEODE CAPITAL MANAGEMENT, LLC added 4,190,487 shares (+10.4%) to their portfolio in Q4 2025, for an estimated $957,484,374
- JPMORGAN CHASE & CO removed 4,141,493 shares (-7.3%) from their portfolio in Q4 2025, for an estimated $946,289,735
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ABBV Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 12/10/2025
- Guggenheim issued a "Buy" rating on 10/20/2025
To track analyst ratings and price targets for ABBV, check out Quiver Quantitative's $ABBV forecast page.
ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 13 analysts offer price targets for $ABBV in the last 6 months, with a median target of $250.0.
Here are some recent targets:
- Carter Gould from Cantor Fitzgerald set a target price of $240.0 on 04/08/2026
- Trung Huynh from RBC Capital set a target price of $260.0 on 02/25/2026
- Emily Field from Barclays set a target price of $275.0 on 02/20/2026
- David Amsellem from Piper Sandler set a target price of $299.0 on 02/18/2026
- Michael Yee from UBS set a target price of $230.0 on 02/05/2026
- Terence Flynn from Morgan Stanley set a target price of $270.0 on 02/05/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $228.0 on 02/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
